Cubist Pharms Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CUBIST PHARMS LLC, and what generic alternatives to CUBIST PHARMS LLC drugs are available?
CUBIST PHARMS LLC has six approved drugs.
There are twenty-nine US patents protecting CUBIST PHARMS LLC drugs.
There are three hundred and forty-one patent family members on CUBIST PHARMS LLC drugs in fifty-three countries and fifty-five supplementary protection certificates in eighteen countries.
Summary for Cubist Pharms Llc
International Patents: | 341 |
US Patents: | 29 |
Tradenames: | 5 |
Ingredients: | 4 |
NDAs: | 6 |
Drugs and US Patents for Cubist Pharms Llc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cubist Pharms Llc | DIFICID | fidaxomicin | TABLET;ORAL | 201699-001 | May 27, 2011 | AB | RX | Yes | Yes | 7,863,249*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Cubist Pharms Llc | DIFICID | fidaxomicin | FOR SUSPENSION;ORAL | 213138-001 | Jan 24, 2020 | RX | Yes | Yes | 7,906,489*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Cubist Pharms Llc | DIFICID | fidaxomicin | FOR SUSPENSION;ORAL | 213138-001 | Jan 24, 2020 | RX | Yes | Yes | 7,863,249*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | POWDER;INTRAVENOUS | 205436-001 | Jun 20, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435-001 | Jun 20, 2014 | RX | Yes | Yes | 9,624,250 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Cubist Pharms Llc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | 6,468,967 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 6,852,689 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 5,912,226 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | 8,129,342 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | 5,912,226 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | 8,058,238 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUBIST PHARMS LLC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2015-05-27 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-11-19 |
International Patents for Cubist Pharms Llc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
New Zealand | 601347 | ⤷ Try a Trial |
Brazil | PI0519890 | ⤷ Try a Trial |
Netherlands | 300727 | ⤷ Try a Trial |
Hungary | S1500016 | ⤷ Try a Trial |
Canada | 2781666 | ⤷ Try a Trial |
Brazil | 0315188 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cubist Pharms Llc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1539977 | 366 50006-2015 | Slovakia | ⤷ Try a Trial | OWNER(S): MERCK SHARP & DOHME LLC, RAHWAY, NJ, US; PREDCHADZAJUCI MAJITEL: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US; DATUM ZAPISU DO REGISTRA: 7.10.2022 |
1115417 | 06C0022 | France | ⤷ Try a Trial | PRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119 |
1539977 | SPC/GB15/020 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FIDAXOMICIN; REGISTERED: UK EU/1/11/733/001 20111207; UK EU/1/11/733/002 20111207; UK EU/1/11/733/003 20111207; UK EU/1/11/733/004 20111207 |
1115417 | SPC/GB06/024 | United Kingdom | ⤷ Try a Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021. |
1539977 | 300727 | Netherlands | ⤷ Try a Trial | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE |
1115417 | SZ 22/2006 | Austria | ⤷ Try a Trial | PRODUCT NAME: DAPTOMYCIN |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.